Skip to content
Research Article Open access CC BY 3.0

Hepcidin: A New Noninvasive Biomarker for Histological Cirrhosis in Hepatitis C Virus Patients

Hanan El-Bassat, Lobna Aboali, Hanan Alshenawy, Atif Taha, Rasha A. Alm El-Din

International Journal of TROPICAL DISEASE & Health · pp. 362–373 · Published 24 Jan 2014

10.9734/IJTDH/2014/5922

Abstract

Aim: To investigate the potential role of serum hepcidin as a biomarker for histological cirrhosis in hepatitis C virus patients. Methods: Serum hepcidin was measured in 80 patients with hepatitis C virus and 15 age and sex matched healthy subjects as control. Liver biopsy was available for 50 patients only. All subjects were divided as follows: Group I: 50 patients with chronic HCV waiting for treatment decision. They were subdivided according to liver fibrosis stage into: Group I (a): 39 patients with fibrosis stage F1, F2 and F3. Group I (b): 11 patients with histological cirrhosis F4. Group II: 30 HCV cirrhotic patients. Group III: 15 age- and sex-matched healthy subjects as control. Results: Serum hepcidin concentration was significantly lower in patients with chronic HCV, histological cirrhosis and cirrhotic patients than healthy control and was lowest in those with cirrhosis (PË‚0.001). Serum hepcidin level was significantly positively correlated with serum ferritin, transferrin saturation, ALT, AST, hemoglobin level, albumin and hepatic iron but negatively correlated with serum bilirubin. Serum hepcidin decrease with progression of liver fibrosis and was lowest in those with histological cirrhosis and clinically proven cirrhosis. In contrast, serum ferritin increased progressively with increasing stages of fibrosis and was highest in those with histological cirrhosis and cirrhotic patients. Conclusions: Increasing hepatic fibrosis is associated with decreased hepcidin serum level. This indicates that hepcidin may serve as a potential biomarker for fibrosis and cirrhosis. Hepcidin is positively correlated with hepatic iron and liver enzymes but negatively correlated with the stage of fibrosis.

Hepcidin iron overload HCV cirrhosis

References (31)

  1. 1 Design and validation of a histological scoring system for nonalcoholic fatty liver disease† [DOI]
  2. 2 Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization [DOI]
  3. 3 An Algorithm for the Grading of Activity in Chronic Hepatitis C [DOI]
  4. 4 Hepatocellular carcinoma in cirrhosis: Incidence and risk factors [DOI]
  5. 5 Fundamentals of Clinical Chemistry. [DOI]
  6. 6 Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver [DOI]
  7. 7 Hepcidin and iron regulation, 10 years later [DOI]
  8. 8 Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation [DOI]
  9. 9 Serum hepcidin: reference ranges and biochemical correlates in the general population [DOI]
  10. 10 Hepatitis C virus–induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity [DOI]
  11. 11 Hepatitis C Virus–Induced Reactive Oxygen Species Raise Hepatic Iron Level in Mice by Reducing Hepcidin Transcription [DOI]
  12. 12 Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C [DOI]
  13. 13 Advances in Quantitative Hepcidin Measurements by Time-of-Flight Mass Spectrometry [DOI]
  14. 14 Reduced serum hepcidin levels in patients with chronic hepatitis C [DOI]
  15. 15 Hemosiderosis in cirrhosis: A study of 447 native livers [DOI]
  16. 16 A Reappraisal of Hepatic Siderosis in Patients With End-Stage Cirrhosis: Practical Implications for the Diagnosis of Hemochromatosis [DOI]
  17. 17 Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C [DOI]
  18. 18 Hepcidin modulation in human diseases: From research to clinic [DOI]
  19. 19 The Changing Epidemiology and Natural History of Hepatitis C Virus Infection [DOI]
  20. 20 Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C [DOI]
  21. 21 Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion [DOI]
  22. 22 The serum hepcidin:ferritin ratio is a potential biomarker for cirrhosis [DOI]
  23. 23 Serum hepcidin levels are related to the severity of liver histological lesions in chronic hepatitis C [DOI]
  24. 24 Evaluation of the First Commercial Hepcidin ELISA for the Differential Diagnosis of Anemia of Chronic Disease and Iron Deficiency Anemia in Hospitalized Geriatric Patients [DOI]
  25. 25 Iron overload in cirrhosis— HFE genotypes and outcome after liver transplantation [DOI]
  26. 26 Histological Evaluation of Iron in Liver Biopsies: Relationship To Hfe Mutations [DOI]
  27. 27 Liver hepcidin mRNA correlates with iron stores, but not inflammation, in patients with chronic hepatitis C.
  28. 28 Hepcidin: a molecular link between inflammation and anaemia [DOI]
  29. 29 Hepcidin mRNA level as a parameter of disease progression in chronic hepatitis C and hepatocellular carcinoma.
  30. 30 The nexus of iron and inflammation in hepcidin regulation: SMADs, STATs, and ECSIT [DOI]
  31. 31 Role of Hepcidin in the Regulation of Iron Metabolism in Patients with Chronic Liver Diseases

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

6

Page views

0

PDF downloads

1

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.